Nucleic acid-based medications such as mRNA vaccines offer tremendous po-tential for medicine and are opening up new therapeutic approaches. These active ingredients must be enclosed inside nanoparticles to ensure that they get to where they are needed inside the body’s cells. The Fraunhofer Institute for Production Systems and Design Technology IPK and FDX Fluid Dynamix GmbH have worked together to develop a technology platform for the pro-duction of nanoparticles that can achieve particle quality and stability at levels previously out of reach: FDmiX, short for Fraunhofer Dynamic Mixing Technologies. Swiss chemical and pharmaceutical company Lonza has now licensed the technology for its own good manufacturing practice (GMP) production activities.
Developing a tech platform for fast, robust series production of nanoparticles phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.